Shots:
- Alvotech & STADA expand their strategic collaboration covering AVT03, biosimilar of Prolia/Xgeva (denosumab), to treat osteoporosis & cancer-related bone loss, respectively
- As per the agreement, AVT03 will be developed & manufactured by Alvotech at its state-of-the-art facility while STADA becomes marketing authorization holder with semi-exclusive commercial rights across the EU, incl. Switzerland & the UK and exclusive rights in certain countries across Central Asia & the Middle East
- Furthermore, STADA gets commercial rights to the biosimilars of Humira & Stelara across Commonwealth of Independent States (CIS) countries in Central Asia while Alvotech reclaims commercial rights of AVT06, biosimilar of Eylea, from STADA
Ref: Alvotech | Image: Alvotech & STADA| Press Release
Related News:- Bio-Thera Gains the CHMP’s Positive Opinion of Avzivi (Biosimilar, Avastin)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
